Ayala Pharmaceuticals, Inc.
MONMOUTH JUNCTION, NJ · CIK 0001100397 · Biotech · Public
Small molecule therapeutic compounds for oncology indications
ayalapharma.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $45M
- 14 Form D · Nov 2023
- 35 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 25
- 0 granted · 25 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓200820102012201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $961,650 | |
| Private capital raised | Form D · SEC | $5,000,000 | |
| Private capital raised | Form D · SEC | $50,000 | |
| Private capital raised | Form D · SEC | $7,500,000 | |
| Private capital raised | Form D · SEC | $835,000 | |
| Private capital raised | Form D · SEC | $6,016,250 | |
| Private capital raised | Form D · SEC | $1,977,500 | |
| Private capital raised | Form D · SEC | $1,047,500 | |
| Private capital raised | Form D · SEC | $4,473,673 | |
| Private capital raised | Form D · SEC | $715,000 | |
| Private capital raised | Form D · SEC | $10,000,000 | |
| Private capital raised | Form D · SEC | $11,093,521 | |
| Private capital raised | Form D · SEC | $4,750,000 | |
| Private capital raised | Form D · SEC | $433,825 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2635 | Amalgent Therapeutics, LLC | — | $200K |
| 2636 | Rapport Therapeutics | — | — |
| 2637 | COSMICA Inc. | — | $200K |
| 2638 | Ayala Pharmaceuticals, Inc. | — | $45M |
| 2639 | YOUNG THERAPEUTICS, LLC | — | — |
| 2640 | Avant Sciences, Inc. | — | $175K |
| 2641 | Renova Therapeutics, Inc. | — | $167K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Roni AppelDirector
- RONI APPELDirector
- Ken BerlinDirector · Executive Officer
- Kenneth BerlinDirector · Executive Officer
- Richard BermanDirector
- RICHARD BERMANDirector
- Vered Bisker-LeibDirector
- Yuval CabillyDirector
- Fredrick CobbExecutive Officer
- Igor GitelmanDirector · Executive Officer
- Roy GolanExecutive Officer
- Murray GoldbergDirector
- Andres GutierrezExecutive Officer
- Samir KhleifDirector
- Bridget MartellDirector
- Thomas McKearnDirector
- THOMAS MCKEARNDirector
- Thomas MooreDirector · Executive Officer
- THOMAS MOOREDirector · Executive Officer
- Pini OrbachDirector
- James PattonDirector
- JAMES PATTONDirector
- Mark RosenblumExecutive Officer
- MARK ROSENBLUMExecutive Officer
- John RothmanExecutive Officer
- JOHN ROTHMANExecutive Officer
- David SidranskyDirector
- Robert SpiegelDirector
Patents
- BISFLUOROALKYL-1,4-BENZODIAZEPINONE Compounds For Treating Desmoid Tumorsapplication
- Combination Of Immunotherapeutics And BISFLUOROALKYL-1,4-BENZODIAZEPINONE Compounds For Treating Cancerapplication
- Combination Of Immunotherapeutics And BISFLUOROALKYL-1,4-BENZODIAZEPINONE Compounds For Treating Lymphomasapplication
- Compositions Comprising BISFLUOROALKYL-1,4-BENZODIAZEPINONE Compounds For Treating Adenoid Cystic Carcinomaapplication
- Compositions Comprising BISFLUOROALKYL-1,4-BENZODIAZEPINONE Compounds For Treating Cancerapplication
- Combinations Of BCL-2 Inhibitors And Gamma Secretase Inhibitors And Related Methods Of Useapplication
- Methods Of Preparing Chiral Benzodiazepinone Derivativesapplication
- Compositions Comprising BISFLUOROALKYL-1,4-BENZODIAZEPINONE Compounds For Treating Adenoid Cystic Carcinomaapplication
- Compositions Comprising BISFLUOROALKYL-1,4-BENZODIAZEPINONE Compounds For Treating Adenoid Cystic Carcinomaapplication
- BISFLUOROALKYL-1,4-BENZODIAZEPINONE Compounds For Treating Notch-activated Breast Cancerapplication
- Methods Of Preparing Chiral Benzodiazepinone Derivativesapplication
- BISFLUOROALKYL-1,4-BENZODIAZEPINONE Compounds For Treating Notch Altered Breast Cancerapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.